A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2023-06-07
AEs
4
Serious
1
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-07-02 (study day 8); relationship: not assessed
mild
assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-10-12 (study day 110); relationship: not assessed
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-01-15 (study day 205); relationship: not assessed
severe
serious
assessed
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-01-20 (study day 210); relationship: N; serious criteria: hospitalization
Data queries
No data queries.